ALNY vs. ARGX: Alnylam Pharmaceuticals vs. argenx Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and argenx (ARGX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and argenx (ARGX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ALNY | ARGX |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | argenx SE American Depositary Receipt |
| Country/Region | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 58.31 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | May 18, 2017 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Total Return (1Y) | -64.57% | 11.91% |
| Total Return (3Y, Annualized) | -1.58% | 25.68% |
| Total Return (5Y, Annualized) | -3.13% | 24.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 37.87% |
| Beta (5Y) | 0.45 | 0.45 |
| Max Drawdown (5Y) | -68.25% | -38.20% |
| Avg. Volume (3M) | 1.90M | 359.84K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.20 |
| Sortino Ratio (1Y) | -1.45 | 0.31 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Alnylam Pharmaceuticals (ALNY) earns 138.07% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and argenx (ARGX) at 31.73% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and argenx (ARGX) at 36.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| ROE (TTM) | 138.07% | -- |
| ROA (TTM) | 9.51% | -- |
| Net Margin (TTM) | 52.85% | 31.73% |
| Operating Margin (TTM) | 23.72% | 36.27% |
| Gross Margin (TTM) | 77.28% | 59.84% |
Growth
Revenue Growth
Both Alnylam Pharmaceuticals (ALNY) at 65.19% and argenx (ARGX) at 89.64% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.
EPS Growth
Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 89.64% |
| Revenue Growth (3Y CAGR) | 52.98% | 116.25% |
| EPS Growth (YoY) | -- | 53.13% |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Alnylam Pharmaceuticals (ALNY) shows current ratio of 2.48 against its industry benchmark, while argenx (ARGX) has no reading this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | -- |
| Debt / Equity (MRQ) | 0.83 | 0.01 |
| Net Debt / EBITDA | -0.57 | -2.70 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor argenx (ARGX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor argenx (ARGX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while argenx (ARGX) at 32.12 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and argenx (ARGX) at 9.86 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | ARGX |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 32.12 |
| P/S Ratio (TTM) | 4.17 | 9.86 |
| P/B Ratio (MRQ) | 5.79 | 172.23 |
| Free Cash Flow Yield (TTM) | 1.57% | -- |